Bayer AG (XSWX:BAYN) Growth Rank: 1 (As of Jul. 09, 2026) — 80% Below Median


XSWX:BAYN Bayer AG XSWX:BAYN
35 GF Score
Price CHF45.72
GF Value CHF24.67
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Growth Rank?

Bayer AG XSWX:BAYN -5.87% 35 Growth Rank is 1 as of Jul. 09, 2026, which is 80% below its 10-year median of 5.00. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bayer AG has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

XSWX:BAYN vs LLY, JNJ, ABBV: Growth Rank Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bayer AG Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Growth Rank distribution charts can be found below:

* The bar in red indicates where Bayer AG's Growth Rank falls into.


XSWX:BAYN
35GF Score
Bayer AG XSWX:BAYN
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Bayer AG (XSWX:BAYN) has a Growth Rank of 1 as of Jul. 09, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Bayer AG and its competitors. This is 80% below median its historical median of 5.00. Over the past decade, Bayer AG's Growth Rank has ranged from 1.00 to 10.00.
Is Bayer AG's Growth Rank too high?
Bayer AG's current Growth Rank of 1 is 80% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Growth Rank compare to LLY and JNJ?
Bayer AG's Growth Rank of 1 can be compared against companies in the Drug Manufacturers industry. Historically, Bayer AG's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Bayer AG and its competitors. Bayer AG's current Growth Rank is 1, which is 80% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF45.72 — trading 85.3% above its estimated fair value. The current Growth Rank is 1, which is 80% below median its 10-year median of 5.00. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Growth Rank is 1 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF45.72 is trading 85.3% above its estimated GF Value™ of CHF24.67. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Growth Rank: 1 (80% below median its 10-year median of 5.00)
  • GF Value™: CHF24.67 vs. price of CHF45.72 (85.3% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score

Get the complete analysis for XSWX:BAYN

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF45.72
Price
CHF24.67
GF Value